Beijing Tiantan Biological Products
Beijing
About Beijing Tiantan Biological Products
Beijing Tiantan Biological Products Co., Ltd. (referred to as "Tiantan Biological Products") is engaged in vaccines, blood products, diagnostic products and other biological products, production and operation of enterprises, in 1998 by the Beijing Institute of Biological Products (formerly 1919 Northern Government Department established in the central epidemic prevention, is the cradle of Chinese biological products) launched listed on the Shanghai Stock Exchange, now the controlling shareholder is China National pharmaceutical Group Corporation. With the development of the company now has subsidiaries Changchun Chi-Biological Products Co., Ltd., a number of apheresis plasma companies. Tiantan Biological has 110 kinds of products, including hepatitis B vaccine, polio vaccine, MMR vaccine, Japanese encephalitis vaccine, influenza vaccine, varicella vaccine, human serum albumin, intravenous human immunoglobulin and other varieties, national immunization program vaccine is an important production base. Listed decades, the company accumulated dividends 477 million yuan, the total assets of the company, the main revenue, total profits have achieved more than 400% growth. Companies in 2006--2008 for three consecutive years won the "Golden Round Table Award for outstanding board of directors" award, won the 10th (2007) Chinese Listed Companies "Golden Bull Award shareholder returns hundred" and other awards.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $500K – $1M
- Ticker: sse:600161
- Website: tiantanbio.com
- Phone: +01060963333
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/beijing-tiantan-biological-products-2280992 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.